Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Manish Sheth

Psychiatry San Diego, CA Medical Doctor

NPI 1225083272 CMS profile 10320

4510 Executive Dr, Suite 115, San Diego, CA 92121

Open in the dashboard

General payments

$9,895

406 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Manish Sheth of San Diego, CA is reported in the CMS Open Payments database as having received $9,895 across 406 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,833 55
2024 General $1,004 37
2023 General $1,415 62
2022 General $1,617 79
2021 General $1,529 67
2020 General $977 44
2019 General $1,521 62

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Manish Sheth
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Manish Sheth were reported at $1,833. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Manish Sheth Psychiatry median Middle half National median
2019 $1,521 $184 $59–$605 $163
2020 $977 $119 $36–$372 $114
2021 $1,529 $143 $43–$576 $132
2022 $1,617 $153 $50–$590 $149
2023 $1,415 $170 $56–$651 $160
2024 $1,004 $179 $57–$673 $164
2025 $1,833 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $1,784 68 payments
  2. Otsuka America Pharmaceutical, Inc. $906 46 payments
  3. Lundbeck LLC $861 40 payments
  4. AbbVie, Inc. $798 42 payments
  5. ITI, Inc. $685 26 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $630 34 payments
  7. Neurocrine Biosciences, Inc. $623 15 payments
  8. Vanda Pharmaceuticals Inc. $486 20 payments
  9. Axsome Therapeutics, Inc. $426 18 payments
  10. Sunovion Pharmaceuticals Inc. $313 14 payments
  11. Other $2,385 83 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,895 406 payments
Products named General payments · program years 2019–2025
  1. SPRAVATO $1,491 46 payments
  2. REXULTI Psychiatry $802 41 payments
  3. INVEGA SUSTENNA $735 39 payments
  4. REXULTI Psychiatry $719 33 payments
  5. VRAYLAR $644 34 payments
  6. CAPLYTA $637 24 payments
  7. TRINTELLIX $533 28 payments
  8. HETLIOZ $486 20 payments
  9. INGREZZA $481 8 payments
  10. Auvelity $426 18 payments
  11. Other $4,610 194 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

406 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record